Alex Birch
About Alex Birch
Alex Birch is a Senior Associate Scientist at Bristol Myers Squibb in Cambridge, Massachusetts, with extensive experience in biotherapeutics and a background in biology and business administration.
Company
Alex Birch is currently employed at Bristol Myers Squibb, working in their Cambridge, Massachusetts, office. The focus area of Alex's work at Bristol Myers Squibb aligns with the role of a Senior Associate Scientist.
Title
Alex Birch holds the title of Senior Associate Scientist. This position involves significant responsibilities in research and development, contributing to the company's projects and innovation in biotherapeutics.
Education and Expertise
Alex Birch acquired a Bachelor of Science (B.S.) in Biology from Northeastern University, a program spanning five years from 2009 to 2014. Furthering academic pursuits, Alex is also pursuing a Master of Business Administration (MBA) at the Isenberg School of Management, UMass Amherst, with an expected completion in 2024. Alex's educational background is complemented by substantial expertise in bioinformatics, analytical techniques, and the production of biotherapeutics.
Work Experience
Alex Birch has an extensive work history in the pharmaceutical and biomedical research sectors, starting with an Analytical Development Co-op role at Selecta Biosciences in 2012. Subsequent positions included roles at Acceleron Pharma, Novartis Institutes for BioMedical Research (NIBR), and Pfizer. At Pfizer, Alex served as Senior Associate Scientist within the BioMedicine Design group from 2016 to 2021. These experiences have provided Alex with significant exposure to analytical development, protein analytics, and biotherapeutic production.
Achievements
Alex Birch has contributed to the research and development of two FDA-approved therapies and led several projects that reached significant milestones. Notably, Alex was the line function lead on a candidate product that reached its first-in-human phase I dose in Q1 2020. Alex also mentored eight individuals, played a crucial role in the rollout of new automation and bioinformatics screening initiatives, and scored a 6.0 on the GRE Analytical Writing portion in January 2021.